|
|
1246 University Avenue W. Suite 205
Saint Paul, MN 55104 USA
phone:(651) 209-0700
fax:
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
2002 |
| Employees |
|
|
|
| www.algosinc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development of drugs for the treatment of chronic pain. |
|
| Management |
| Susanne C. Dvorak, CEO; Todd A. Verdoom, CSO and COO |
| |
|
|
| |
|
| Keywords |
| drug discovery, diabetic neuropathy, post-herpetic neuralgia, lower back pain, intractable cancer pain |
|
|
|
| Description |
|
Seeking investor relations, this company is focused on the discovery and development of breakthrough drugs for the treatment of chronic pain. Algos' internal research program is based on its substantial intellectual property (IP) portfolio. Algos Therapeutics is committed to becoming the preeminent pain-focused drug discovery company with the goal of developing breakthrough treatments for painful conditions such as diabetic neuropathy, post-herpetic neuralgia, lower back pain, and intractable cancer pain. |
|
| Products / Services |
The technology infrastructure of Algos Therapeutics will consist of core intellectual property and unique scientific capabilities. Algos owns a proprietary portfolio of intellectual property, scientific knowledge and research tools that will propel an active internal research program This collection of knowledge represents an exceptionally strong scientific basis from which to build a strong drug discovery program because it provides a unique understanding of the causes and potential treatment strategies for chronic pain states.
|
|
| Technology / Differentiation |
| They work to design and execute flexible pain research programs in areas such as: chronic neuropathic pain (nerve injury models; diabetes models), chronic inflammatory pain (acute inflammatory pain; visceral pain and hypersensitivity), future models, bone cancer and joint pain. |
|
| Market / Customers |
Worldwide sales of pain drugs exceed $25 billion and are growing rapidly. Effective treatment of chronic pain remains a highly-unmet medical need and commercial opportunity. Pharmaceutical companies are increasingly outsourcing animal testing of new potential pain drugs to improve efficiencies in their research, creating business opportunities for Algos. Algos has senior level contacts within the pharmaceutical and biotechnology industry and established customer relationships with many of the world's leading pain research organizations as well as smaller bio-pharma research groups that make up its target market.
|
|
| Competitors / Substitutes / Alternatives |
Most pharmaceutical and many biotech companies are pursuing various strategies to develop new pain drugs. The Algos IP is unique. The competitors of Algos are also the company's customers and collaborators.
|
|
|
Additional Information |
| awaiting content update |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members